PAA
KITE

Peregrine Asset Advisers’s Kite Pharma, Inc. KITE Stock Holding History

Peregrine Asset Advisers’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,000
Closed -$250K – 123
2016
Q2 		$250K Buy
+5,000
New +$246K 0.17% 89
2014
Q4 		– Sell
-48,490
Closed -$1.38M – 143
2014
Q3 		$1.38M Buy
+48,490
New +$1.2M 1.14% 32

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Peregrine Asset Advisers's KITE Position: Q3 2016 in Review

Peregrine Asset Advisers sold out of Kite Pharma, Inc. (KITE) in Q3 2016, closing a stake of 5,000 shares — an estimated $250K sold.

Peregrine Asset Advisers first reported a position in KITE in Q3 2014 and held it in 2 quarters. The position peaked at $1.38M in Q3 2014. 195 funds tracked by Wall St. Rank hold KITE as of Q3 2016.

  • Peregrine Asset Advisers reported no remaining Kite Pharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Peregrine Asset Advisers sold 5,000 Kite Pharma, Inc. shares in Q3 2016, an estimated $250K.
  • Peregrine Asset Advisers first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 2 quarters.
  • Peregrine Asset Advisers's Kite Pharma, Inc. position peaked at $1.38M in Q3 2014.
  • 195 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2016.

Based on Peregrine Asset Advisers's 13F filing for Q3 2016, filed 14 Nov 2016.